2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COVID-19: in the absence of vaccination – ‘mask-the-nation’

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Coronavirus (CoV) disease 2019 (COVID-19) is a severe respiratory illness first reported in Wuhan, the capital city of Hubei Province, China. The first patient to be hospitalized with COVID-19 was admitted on 12 December 2019 [1]. The symptoms of the disease include fever, an unproductive cough, muscular soreness and dyspnea [2]. Predominantly affecting older people, particularly those with underlying medical conditions, COVID-19 has an estimated mortality rate of 2–5% [3]. The causative agent of COVID-19 is a CoV; named SARS-CoV-2 by the WHO on 11 February 2020 (the same day the disease itself was officially named) [4]. Phylogenetic analysis revealed that the virus is most closely related to a group of SARS-like CoVs (genus Betacoronavirus, subgenus Sarbecovirus) previously isolated from bats in China [1]. Among this group is SARS-CoV, the causative agent of SARS. On 11 March 2020, the WHO declared the COVID-19 outbreak a global pandemic [5]. At the time of writing, 213 countries and territories around the world and two international conveyances have reported cases of COVID-19, with the total number surpassing 10 million and over 500,000 associated deaths [6]. While these numbers make for painful reading, the situation could have been significantly worse had it not been for the strict social distancing and isolation measures imposed by most nations in a concerted effort to ‘flatten the curve’ [7]. However, as these measures are eased and at least some sectors of society return to work, we need to consider what procedures are now required to continue protecting a post-lockdown population [8]. In the absence of a vaccine, or effective antiviral, one of our only remaining strategies for controlling COVID-19 is to physically block the spread of SARS-CoV-2 in the community. Given that COVID-19 is a respiratory illness, the most effective physical defense likely involves widespread public use of face coverings, in conjunction with other control measures [9]. Face coverings (also variously referred to as face masks, nonmedical masks, community masks or barrier masks) function primarily in source control; capturing droplets expelled by an infected individual [10]. Droplet spread is widely considered to be the main mode of transmission of SARS-CoV-2 [11]. Small aerosols are created by rupture of bubbles, or thin films, in the bronchioles of the lungs and vocal cords when speaking. Larger droplets >10 μm fail to traverse the 90° bend of the throat, but can be created in the mouth during speech, coughing and sneezing [12]. There is significant uncertainty, to date, as to what size range is most infectious and, even in a single patient, the distribution of SARS-CoV-2 in the respiratory tract appears to vary widely [13]. However, it is known that expelled particles as large as 100 μm can travel more than 2 m in realistic scenarios [14], and due to the much larger volume, can potentially carry a significant viral load and associated infection risk. Once expelled, droplets evaporate to droplet nuclei (which, being ∼tenfold lighter, remain airborne for longer, thus potentially increasing transmission rates [15]). Despite some early concerns relating to the benefits of public masking in preventing viral spread (specifically influenza virus) [16], a recent meta-analysis by Chu et al. [17], involving 172 observational studies across 16 countries and six continents, strongly suggests that face masks reduce the spread of SARS-CoV-2. Macintyre and Chughtai [18] support this view, suggesting that all sectors of society (the community, sick and healthcare workers) will benefit from masking. Indeed, this growing consensus is in line with the findings from the 2003 SARS outbreak in Hong Kong, which show that widespread public use of face masks, together with frequent hand washing and living quarter disinfection, significantly reduced the risk of viral transmission [19]. This, together with evidence from trials with other epidemic respiratory viruses [20], suggests that widespread public masking might be a useful strategy in controlling community spread of SARS-CoV-2. However, despite this, until recently there has been a reluctance by public health administrators to embrace universal public masking [21]. This reticence centers mainly on two key concerns [9]. First, public demand is likely to lead to even further shortages in already stretched healthcare settings [22]. The second issue relates to potential carelessness and complacency in the general population. While carelessness speaks to inappropriate mask usage (i.e., ill fitting or improperly donned masks), the complacency issue centers on a false sense of security which may accompany mask usage; leading to reduced adherence to other necessary control measures, as previously reported by Yan et al. [23]. In line with the most recent public health recommendations [24], and in the absence of an available vaccine or effective antiviral, we suggest that properly designed ‘do it yourself’ (DIY) face masks, fabricated from common household materials, represent the most efficient means of controlling community spread of SARS-CoV-2 (particularly when used in conjunction with appropriate social distancing and hand hygiene practices). DIY face masks reduce demand for medical grade personal protective equipment (PPE) such as N95 masks, thereby safeguarding the medical supply chain and protecting healthcare workers [25]. Furthermore, depending on the materials used, properly designed DIY face masks are often easier to use and more comfortable to wear for prolonged periods. While not as effective as PPE [26], several studies have shown that masks fashioned from common household materials (including tea cloths [27], pillowcases [28] and T-shirts [29]) are at least partially effective in blocking viral spread. Indeed, Zhao et al. [30] have helped to quantify the approach using a ranking system (based on filtration quality factor, fabric microstructure and charging ability), to identify the most effective household materials for DIY mask fabrication. Proof of concept for the DIY approach is provided, at least in part, by Ma et al., [31], who have recently shown that homemade masks, composed of four layers of kitchen paper and one layer of cloth, could block 95.15% of the avian influenza virus, compared with 99.98% for N95 masks and 97.14% for surgical masks. To be effective, everyone, irrespective of whether they are symptomatic or not, should be advised to wear a face covering in public (particularly in situations where appropriate social distancing is either impractical or impossible). This totalitarian approach serves two purposes: first, it overcomes the stigma associated with wearing a mask in public (previously considered by Buregyeya et al. [32], in relation to TB patients). Second, it reduces spread by asymptomatic carriers. This is particularly important in the case of SARS-CoV-2, whereby the viral load has been shown to be similar in symptomatic and asymptomatic patients [33], and infection from an asymptomatic contact has already been reported [34]. Furthermore, universal public masking has the added benefit of protecting against other respiratory infectious agents, such as influenza virus [35]. Indeed, co-infection by SARS-CoV-2 and Influenza virus has already been reported in both China [36] and Iran [37]. Encouragingly, and in support of the above, Cowling et al. [38] have shown that nonpharmaceutical interventions, including face masks, resulted in a 44% reduction in influenza transmissibility in Hong Kong, in the midst of the current COVID-19 pandemic. Thus, in the absence of a vaccination strategy, DIY face masks will likely play an important role in stemming the spread of SARS-CoV-2. We conclude by introducing a new idiom to the epidemiology lexicon: in the absence of vaccination, mask-the-nation!

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A new coronavirus associated with human respiratory disease in China

          Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health 1–3 . Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty. A severe respiratory disease was recently reported in Wuhan, Hubei province, China. As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan. Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough. Metagenomic RNA sequencing 4 of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here ‘WH-Human 1’ coronavirus (and has also been referred to as ‘2019-nCoV’). Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China 5 . This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Virological assessment of hospitalized patients with COVID-2019

            Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 × 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              WHO Declares COVID-19 a Pandemic

              The World Health Organization (WHO) on March 11, 2020, has declared the novel coronavirus (COVID-19) outbreak a global pandemic (1). At a news briefing, WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, noted that over the past 2 weeks, the number of cases outside China increased 13-fold and the number of countries with cases increased threefold. Further increases are expected. He said that the WHO is “deeply concerned both by the alarming levels of spread and severity and by the alarming levels of inaction,” and he called on countries to take action now to contain the virus. “We should double down,” he said. “We should be more aggressive.” Among the WHO’s current recommendations, people with mild respiratory symptoms should be encouraged to isolate themselves, and social distancing is emphasized and these recommendations apply even to countries with no reported cases (2). Separately, in JAMA, researchers report that SARS-CoV-2, the virus that causes COVID-19, was most often detected in respiratory samples from patients in China. However, live virus was also found in feces. They conclude: “Transmission of the virus by respiratory and extrarespiratory routes may help explain the rapid spread of disease.”(3). COVID-19 is a novel disease with an incompletely described clinical course, especially for children. In a recente report W. Liu et al described that the virus causing Covid-19 was detected early in the epidemic in 6 (1.6%) out of 366 children (≤16 years of age) hospitalized because of respiratory infections at Tongji Hospital, around Wuhan. All these six children had previously been completely healthy and their clinical characteristics at admission included high fever (>39°C) cough and vomiting (only in four). Four of the six patients had pneumonia, and only one required intensive care. All patients were treated with antiviral agents, antibiotic agents, and supportive therapies, and recovered after a median 7.5 days of hospitalization. (4). Risk factors for severe illness remain uncertain (although older age and comorbidity have emerged as likely important factors), the safety of supportive care strategies such as oxygen by high-flow nasal cannula and noninvasive ventilation are unclear, and the risk of mortality, even among critically ill patients, is uncertain. There are no proven effective specific treatment strategies, and the risk-benefit ratio for commonly used treatments such as corticosteroids is unclear (3,5). Septic shock and specific organ dysfunction such as acute kidney injury appear to occur in a significant proportion of patients with COVID-19–related critical illness and are associated with increasing mortality, with management recommendations following available evidence-based guidelines (3). Novel COVID-19 “can often present as a common cold-like illness,” wrote Roman Wöelfel et al. (6). They report data from a study concerning nine young- to middle-aged adults in Germany who developed COVID-19 after close contact with a known case. All had generally mild clinical courses; seven had upper respiratory tract disease, and two had limited involvement of the lower respiratory tract. Pharyngeal virus shedding was high during the first week of symptoms, peaking on day 4. Additionally, sputum viral shedding persisted after symptom resolution. The German researchers say the current case definition for COVID-19, which emphasizes lower respiratory tract disease, may need to be adjusted(6). But they considered only young and “normal” subjecta whereas the story is different in frail comorbid older patients, in whom COVID 19 may precipitate an insterstitial pneumonia, with severe respiratory failure and death (3). High level of attention should be paid to comorbidities in the treatment of COVID-19. In the literature, COVID-19 is characterised by the symptoms of viral pneumonia such as fever, fatigue, dry cough, and lymphopenia. Many of the older patients who become severely ill have evidence of underlying illness such as cardiovascular disease, liver disease, kidney disease, or malignant tumours. These patients often die of their original comorbidities. They die “with COVID”, but were extremely frail and we therefore need to accurately evaluate all original comorbidities. In addition to the risk of group transmission of an infectious disease, we should pay full attention to the treatment of the original comorbidities of the individual while treating pneumonia, especially in older patients with serious comorbid conditions and polipharmacy. Not only capable of causing pneumonia, COVID-19 may also cause damage to other organs such as the heart, the liver, and the kidneys, as well as to organ systems such as the blood and the immune system. Patients die of multiple organ failure, shock, acute respiratory distress syndrome, heart failure, arrhythmias, and renal failure (5,6). What we know about COVID 19? In December 2019, a cluster of severe pneumonia cases of unknown cause was reported in Wuhan, Hubei province, China. The initial cluster was epidemiologically linked to a seafood wholesale market in Wuhan, although many of the initial 41 cases were later reported to have no known exposure to the market (7). A novel strain of coronavirus belonging to the same family of viruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), as well as the 4 human coronaviruses associated with the common cold, was subsequently isolated from lower respiratory tract samples of 4 cases on 7 January 2020. On 30 January 2020, the WHO declared that the SARS-CoV-2 outbreak constituted a Public Health Emergency of International Concern, and more than 80, 000 confirmed cases had been reported worldwide as of 28 February 2020 (8). On 31 January 2020, the U.S. Centers for Disease Control and Prevention announced that all citizens returning from Hubei province, China, would be subject to mandatory quarantine for up to 14 days. But from China COVID 19 arrived to many other countries. Rothe C et al reported a case of a 33-year-old otherwise healthy German businessman :she became ill with a sore throat, chills, and myalgias on January 24, 2020 (9). The following day, a fever of 39.1°C developed, along with a productive cough. By the evening of the next day, he started feeling better and went back to work on January 27. Before the onset of symptoms, he had attended meetings with a Chinese business partner at his company near Munich on January 20 and 21. The business partner, a Shanghai resident, had visited Germany between January 19 and 22. During her stay, she had been well with no signs or symptoms of infection but had become ill on her flight back to China, where she tested positive for 2019-nCoV on January 26. This case of 2019-nCoV infection was diagnosed in Germany and transmitted outside Asia. However, it is notable that the infection appears to have been transmitted during the incubation period of the index patient, in whom the illness was brief and nonspecific. The fact that asymptomatic persons are potential sources of 2019-nCoV infection may warrant a reassessment of transmission dynamics of the current outbreak (9). Our current understanding of the incubation period for COVID-19 is limited. An early analysis based on 88 confirmed cases in Chinese provinces outside Wuhan, using data on known travel to and from Wuhan to estimate the exposure interval, indicated a mean incubation period of 6.4 days (95% CI, 5.6 to 7.7 days), with a range of 2.1 to 11.1 days. Another analysis based on 158 confirmed cases outside Wuhan estimated a median incubation period of 5.0 days (CI, 4.4 to 5.6 days), with a range of 2 to 14 days. These estimates are generally consistent with estimates from 10 confirmed cases in China (mean incubation period, 5.2 days [CI, 4.1 to 7.0 days] and from clinical reports of a familial cluster of COVID-19 in which symptom onset occurred 3 to 6 days after assumed exposure in Wuhan (10-12). The incubation period can inform several important public health activities for infectious diseases, including active monitoring, surveillance, control, and modeling. Active monitoring requires potentially exposed persons to contact local health authorities to report their health status every day. Understanding the length of active monitoring needed to limit the risk for missing infections is necessary for health departments to effectively use resources. A recent paper provides additional evidence for a median incubation period for COVID-19 of approximately 5 days (13). Lauer et al suggest that 101 out of every 10 000 cases will develop symptoms after 14 days of active monitoring or quarantinen (13). Whether this rate is acceptable depends on the expected risk for infection in the population being monitored and considered judgment about the cost of missing cases. Combining these judgments with the estimates presented here can help public health officials to set rational and evidence-based COVID-19 control policies. Note that the proportion of mild cases detected has increased as surveillance and monitoring systems have been strengthened. The incubation period for these severe cases may differ from that of less severe or subclinical infections and is not typically an applicable measure for those with asymptomatic infections In conclusion, in a very short period health care systems and society have been severely challenged by yet another emerging virus. Preventing transmission and slowing the rate of new infections are the primary goals; however, the concern of COVID-19 causing critical illness and death is at the core of public anxiety. The critical care community has enormous experience in treating severe acute respiratory infections every year, often from uncertain causes. The care of severely ill patients, in particular older persons with COVID-19 must be grounded in this evidence base and, in parallel, ensure that learning from each patient could be of great importance to care all population,
                Bookmark

                Author and article information

                Journal
                Future Microbiol
                Future Microbiol
                FMB
                Future Microbiology
                Future Medicine Ltd (London, UK )
                1746-0913
                1746-0921
                17 July 2020
                June 2020
                17 July 2020
                : 10.2217/fmb-2020-0112
                Affiliations
                1Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork, Ireland
                2Centre for Advanced Photonics & Process Analysis, Cork Institute of Technology, Bishopstown, Cork, Ireland
                3Blackrock Castle Observatory, Cork Institute of Technology, Bishopstown, Cork, Ireland
                Author notes
                [* ]Author for correspondence: Tel.: +353 214 335 405; roy.sleator@ 123456cit.ie
                Author information
                https://orcid.org/0000-0001-5846-3938
                Article
                10.2217/fmb-2020-0112
                7367512
                32677846
                21a4ab7b-fca1-4a69-86a3-0d86c3f603c4
                © 2020 Future Medicine Ltd

                This work is licensed under the Creative Commons Attribution 4.0 License

                History
                : 15 May 2020
                : 24 June 2020
                : 17 July 2020
                Page count
                Pages: 4
                Categories
                Editorial

                covid-19,coronavirus,face masks,sars,sars-cov-2
                covid-19, coronavirus, face masks, sars, sars-cov-2

                Comments

                Comment on this article